Novo Nordisk CEO Mike Doustdar forecasts oral obesity drugs may comprise half the global market by 2030 as the company advances five oral treatments. Holding over 80% of new oral prescriptions, Novo a
Asian equities trend lower amid rising oil prices and inflation fears, while copper reaches record highs. Corporate updates include Novo Nordisk halting heart disease trials and ADNOc exploring refini
Novo Nordisk halted two additional trials of its experimental heart drug ziltivekimab following earlier failure, hindering efforts to diversify beyond its obesity franchise. One remaining trial will c
Novo Nordisk reported that 40.4% of children aged 6 to under 12 treated with semaglutide were no longer classified as obese after 68 weeks in the STEP Young trial. Safety profiles remained consistent
ChemBrief